Arcturus and Moderna Stocks Drop Following BioNTech's Cancer Vaccine Trial Halt
mRNA drug developers Arcturus Therapeutics (ARCT) and Moderna (MRNA) saw their stocks decline on Friday after a setback in BioNTech’s mid-stage trial for its mRNA-based cancer vaccine BNT122, developed with Roche. The trial was halted due to concerns over the treatment's efficacy. The news negatively impacted investor sentiment across the broader mRNA sector, as companies like Arcturus and Moderna are closely watched within this space. BioNTech’s decision highlights ongoing challenges in developing effective mRNA-based cancer therapies, which could affect future investment flows into related biotech firms.
Tickers: $ARCT $BNTX $MRNA $RHHBY
Topics: cancer vaccines clinical trials mRNA drugs